Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?

Condition(s) targeted: Non-Cardiac Chest Pain

Intervention: Baclofen, Diltiazem (Drug)

Phase: N/A

Status: Terminated

Sponsored by: Chinese University of Hong Kong

Official(s) and/or principal investigator(s):
Justin CY CU, MD, Principal Investigator, Affiliation: Chinese University of Hong Kong

The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese. We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Official title: Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study

Primary outcome: Esophageal sensory and pain thresholds

Secondary outcome:

Symptom severity of chest pain at the end of treatment

Evoked potential responses

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Consecutive patients with monthly angina-like chest pain and negative coronary

angiogram or scintigraphy

- Age between 18-70

- Gastroesophageal reflux disease

- Psychiatric illness

- Cerebrovascular accident

- Active peptic ulceration

- Heart failure or cardiac bradyarrhythmia

- Epilepsy

- Pregnancy or lactating female

- Previous hypersensitivity to muscle relaxant

Endoscopy Centre, Prince of Wales Hospital, Hong Kong, China

Starting date: November 2004
Ending date: January 2007
Last updated: March 25, 2008